On Jul. 6, 2020, Merck announced a new analyses from the Phase 2b trial evaluating the safety and efficacy of islatravir, the companyﾒs investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (PIFELTROﾙ), in adults with HIV-1 infection who had not previously received antiretroviral treatment.